Cagrilintide vs Retatrutide: Amylin Analog vs Triple Agonist Compared (2025 Research)

Cagrilintide and retatrutide sit on opposite sides of the modern metabolic peptide map. One is a single-target amylin analog built for satiety signaling. The other is a triple receptor agonist engineered to hit three metabolic pathways at once. They are frequently searched together because researchers want to understand how a focused, well-tolerated mechanism stacks up against the most aggressive multi-agonist molecule in the pipeline. This guide compares cagrilintide vs retatrutide head to head: receptor targets, half-life, study readouts through 2025, and why cagrilintide is most often studied alongside semaglutide as the combination known as CagriSema rather than against retatrutide directly. Everything below is framed strictly for laboratory and research use only.

Key Takeaways

• Cagrilintide is a long-acting amylin analog (CAS 1415456-99-3) that activates amylin receptors AMY1R to AMY3R and the calcitonin receptor to drive satiety signaling in research models.
• Retatrutide is a triple receptor agonist (CAS 2381089-83-2) that simultaneously stimulates GLP-1, GIP, and glucagon receptors, a fundamentally broader mechanism.
• In published phase 2 work, retatrutide produced mean body weight reductions up to 24.2 percent at 48 weeks in study cohorts, while cagrilintide monotherapy reached roughly 11.8 percent over 68 weeks.
• Cagrilintide is rarely compared to retatrutide in actual trials; instead it is paired with semaglutide as CagriSema, which delivered around 20.4 to 22.7 percent mean reduction in the 2025 REDEFINE 1 readout.
• Both peptides are once-weekly molecules thanks to long elimination half-lives (cagrilintide roughly 159 to 195 hours; retatrutide approximately 6 days).
• There is no published clinical program combining cagrilintide and retatrutide together, a point worth noting for anyone surveying the literature.

Cagrilintide: The Long-Acting Amylin Analog

Cagrilintide, also referenced in early literature as AM833, is a long-acting analog of amylin. Amylin is a hormone co-secreted with insulin from pancreatic beta cells, and its job in the body is to signal fullness. Cagrilintide was developed by modifying the natural amylin backbone so it would survive far longer in circulation.

The molecule is built on a pramlintide-like 37-amino-acid scaffold with key substitutions and N-terminal acylation using a C20 eicosanedioic fatty diacid linked through a gamma-glutamic acid spacer. That fatty acid chain lets the peptide bind albumin in the blood, which is the trick that extends its half-life from the roughly 15 minutes of native amylin to several days. In research characterization, cagrilintide behaves as a non-selective agonist across amylin receptors AMY1R, AMY2R, and AMY3R as well as the calcitonin receptor, acting in the area postrema and hypothalamus.

For lab handling, the reported elimination half-life sits between 159 and 195 hours, which is why investigational dosing schedules in published studies are once weekly. Researchers studying satiety signaling, gastric emptying, and amylin pathway biology often select cagrilintide precisely because it isolates a single mechanism cleanly. You can review specifications for the cagrilintide research peptide on the product page, including third-party HPLC data.

Retatrutide: The Triple Receptor Agonist

Retatrutide is a different class of molecule entirely. It is a synthetic peptide engineered to act as an agonist at three receptors at once: GLP-1, GIP, and glucagon. This triple action is the reason it has attracted so much attention. GLP-1 and GIP activation are associated with appetite regulation and glucose handling in research models, while the added glucagon arm is linked to increased energy expenditure. The combined effect in study cohorts appears additive rather than simply the sum of individual pathways.

In the published phase 2 work, retatrutide reached mean body weight reductions of up to 24.2 percent at 48 weeks at the highest investigational dose in adults without type 2 diabetes, with longer 68-week follow-up data pointing even higher in some analyses. Liver fat changes were also striking in research readouts, with mean relative reductions exceeding 80 percent at higher doses. The most commonly reported adverse signals were gastrointestinal, consistent with the GLP-1 agonist class.

For a deeper look at the triple-agonist mechanism, see our retatrutide triple agonist research guide and the broader retatrutide vs tirzepatide vs semaglutide breakdown.

Cagrilintide vs Retatrutide: Side-by-Side Comparison

The clearest way to understand cagrilintide vs retatrutide is to put their core attributes next to each other. The two molecules are not designed to do the same thing, which is the single most important takeaway.

The table makes the divergence obvious. Retatrutide is the broader, more aggressive molecule by mechanism and by reported magnitude of effect. Cagrilintide is narrower and is generally positioned as a complementary agent rather than a standalone heavyweight.

Why Cagrilintide Is Studied With Semaglutide, Not Retatrutide

A common point of confusion is why researchers rarely test cagrilintide directly against retatrutide. The answer is structural. Cagrilintide's amylin mechanism is complementary to GLP-1 signaling, not redundant with it. That makes pairing cagrilintide with a GLP-1 agonist a logical strategy: two distinct satiety and metabolic pathways engaged together.

This is the entire rationale behind CagriSema, the fixed combination of cagrilintide and semaglutide. In the 2025 REDEFINE 1 readout, the combination produced a mean body weight reduction in the range of 20.4 to 22.7 percent over 68 weeks in study populations, with a large share of participants reaching at least 20 percent reduction. Pairing an amylin analog with a GLP-1 agonist captures additive benefit precisely because the mechanisms do not overlap.

Retatrutide, by contrast, already bundles multiple pathways into one molecule. There is no published clinical program combining cagrilintide and retatrutide together, and that absence is itself informative. For background on related single-mechanism research, see our cagrilintide amylin analog research guide and the semaglutide research guide.

Half-Life, Stability, and Lab Handling

Both peptides are lyophilized powders that require reconstitution before use in research. Cagrilintide's roughly 7-to-8-day functional half-life and retatrutide's approximately 6-day half-life are both products of albumin-binding fatty acid modifications, so handling logic is similar. Reconstituted material should be kept cold and protected from repeated freeze-thaw cycles to preserve integrity.

If your lab is new to either compound, our how to reconstitute research peptides walkthrough and the peptide storage and stability guide cover the fundamentals: bacteriostatic water selection, swirl-don't-shake technique, aliquoting strategy, and refrigeration windows. Purity verification matters too. Every batch we supply ships with a published certificate of analysis, and you can learn what to look for in our how to verify research peptide purity with a COA guide.

Choosing Between Them for Research

The decision is dictated by the research question. Studies isolating amylin receptor biology, satiety signaling, or gastric emptying point toward cagrilintide because it cleanly engages one mechanism. Investigations into multi-pathway metabolic effects, energy expenditure, or hepatic fat dynamics point toward retatrutide because of its triple-agonist breadth.

Researchers exploring combination and additive-effect hypotheses tend to look at cagrilintide alongside a GLP-1 agonist rather than at retatrutide as a comparator, simply because that is where the published evidence base lives. Neither molecule is universally superior. They occupy different roles, and the comparison is less about a winner and more about matching the tool to the experimental design.

Sourcing Cagrilintide and Retatrutide for Research

Material quality is the variable most under your control. Lyze Labs supplies both compounds at 99 percent or higher purity, third-party HPLC tested, with a published COA for every batch so you can confirm identity and concentration before work begins. We are trusted by more than 12,000 researchers across 50-plus countries and hold a 4.8 out of 5 rating from verified buyers.

Demand for GLP-1 and amylin-class research compounds has surged, and batch availability is limited. Securing current batch pricing now protects against the volatility that comes with constrained supply. Shipping is free, discreet, and worldwide, typically arriving in 7 to 14 days. WhatsApp is the fastest order channel, and we also accept Visa, Mastercard, UPI, PayPal, CashApp, bank or wire transfer, and crypto including BTC, USDT, and ETH.

Frequently Asked Questions

What is the main difference between cagrilintide vs retatrutide?

Cagrilintide is a single-mechanism amylin analog that activates amylin and calcitonin receptors to drive satiety signaling, while retatrutide is a triple receptor agonist that simultaneously stimulates GLP-1, GIP, and glucagon receptors. Cagrilintide isolates one pathway; retatrutide engages three at once. They are different classes of research compound designed for different experimental questions.

Which has shown greater weight reduction in studies, cagrilintide or retatrutide?

In published research readouts, retatrutide reached mean body weight reductions of up to 24.2 percent at 48 weeks in study cohorts, whereas cagrilintide monotherapy reached roughly 11.8 percent over 68 weeks. Retatrutide showed the larger magnitude as a standalone agent. Cagrilintide's strongest data comes from its combination with semaglutide rather than from monotherapy.

Why is cagrilintide combined with semaglutide as CagriSema?

Cagrilintide's amylin mechanism is complementary to semaglutide's GLP-1 mechanism, so pairing them engages two distinct satiety and metabolic pathways for an additive effect. In the 2025 REDEFINE 1 study, the CagriSema combination produced mean reductions in the 20.4 to 22.7 percent range over 68 weeks. This is why cagrilintide is studied with semaglutide rather than against retatrutide.

Can cagrilintide and retatrutide be combined in research?

There is no published clinical program combining cagrilintide and retatrutide together, and no registered investigational data exists for that pairing. Retatrutide already incorporates multiple receptor pathways into a single molecule, which reduces the rationale for adding an amylin analog. Any combination work would be exploratory and outside the existing evidence base.

What are the half-lives of cagrilintide and retatrutide?

Cagrilintide has a reported elimination half-life of roughly 159 to 195 hours, and retatrutide has a half-life of approximately 6 days. Both support once-weekly dosing schedules in published studies because of albumin-binding fatty acid modifications that extend their circulation time. Both ship as lyophilized powders requiring reconstitution.

How can I verify the purity of cagrilintide or retatrutide before research?

Request the third-party HPLC certificate of analysis for the specific batch, which confirms purity at 99 percent or higher along with identity and concentration. Lyze Labs publishes a COA for every batch. Our guide on verifying research peptide purity explains how to read the chromatogram, mass spec data, and batch identifiers so you can confirm material quality before any work begins.

Order Cagrilintide for Your Research

Whether your protocol calls for a focused amylin analog or you are mapping the broader metabolic peptide landscape, source material you can verify. View specifications and the published COA on the cagrilintide product page, then message us on WhatsApp to lock in current batch pricing while supply lasts. Free discreet worldwide shipping, 99 percent or higher purity, and a COA in every order, trusted by 12,000-plus researchers across 50-plus countries.